Key clinical point: Pembrolizumab monotherapy is as safe and effective in elderly patients with non–small cell lung cancer as it is younger patients.
Major finding: Elderly patients with NSCLC and a PD-L1 tumor proportion score (TPS) of at least 1% had better median overall survival when treated with pembrolizumab instead of chemotherapy (hazard ratio, 0.76).
Study details: A pooled analysis of patients 75 years or older from KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 phase 3 trials.
Disclosures: The study was funded by MSD. The investigators reported financial relationships with AstraZeneca, Eli Lilly, Taiho, Chugai, and others.
Nosaki et al. ELCC 2019. Abstract 103O_PR.